hotspot -WSS

hotspot

author：focus 2025-10-01 22:49:50 - browse：5

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Listen: Wegovy in the brain & pivotal Alzheimer's data

leisure time

WSS

Listen: Wegovy in the brain & pivotal Alzheimer's data

Listen: Wegovy in the brain & pivotal Alzheimer's data

Menendez indictment could see pharma lose a key ally

Biden tests positive for Covid

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Medicare drug price negotiation program allowed for now

knowledge

hotspot

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Heart attack and stroke risk calculators need revising

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Peter Hotez and the public health issue of online harassment

Custom gene therapy hints at new path for rare disease treatments

United colonoscopy coverage change 'may cost lives,' doctors say

Covid vaccines: Private market messier than government rollout

What does generative AI mean for health care? We asked experts

Biogen shutters digital health group, ends Apple study, in cost cutting move

focus

How Medicaid coverage policies for immigrants impact new moms

After a drawn out lobbying fight, ARPA

Sanofi seeks simpler, safer CRISPR sickle cell cure

Medicare to cover more brain scans for Alzheimer’s patients

AI can’t replace a physician’s gut feeling

How the Dana

hotspot

focus

leisure time

hotspot